Albendazole versus metronidazole treatment of adult giardiasis: An open randomized clinical study.

Abstract

AIM:

To investigate the efficacy and tolerability of albendazole and metranidazole treatment in giardiasis.

METHODS:

The open comparative randomized trial was carried out prospectively from December 1999 to July 2001 in Duzce City of Turkey. The diagnosis was based on the presence of signs and symptoms compatible with giardiasis including a positive stool examination of giardia cysts or trophozoite. Metranidazole group consisted of 29 patients and was given metranidazole 500 mg, three times a day for 5 d and albendazole group was consisted of 28 patients and was given albendazole 400 mg/d for 5 d.

RESULTS:

There were no significant differences in demographical and therapeutical effects and patient's compliance between both groups. But side effects were seen more in metranidazole group than in albendazole group.

CONCLUSION:

Albendazole is as effective as metranidazole in adults' giardiasis. Albendazole has less side effect potentials than metranidazole in the treatment of giardiasis.

• Authors: Oguz Karabay, Ali Tamer, Huseyin Gunduz, Derya Kayas, Huseyin Arinc, Harika Celebi
• Journal: World journal of gastroenterology (World J Gastroenterol) Vol. 10 Issue 8 Pg. 1215-7 (Apr 15 2004) ISSN: 1007-9327 [Print] United States
• PMID: 15069729 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Antiprotozoal Agents
• Antitrichomonal Agents
• Metronidazole
• Albendazole

Topics

• Adult
• Albendazole (administration & dosage)
• Antiprotozoal Agents (administration & dosage)
• Antitrichomonal Agents (administration & dosage)
• Female
• Giardiasis (drug therapy)
• Humans
• Male
• Metronidazole (administration & dosage)
• Middle Aged
• Prospective Studies
• Treatment Outcome